Mark Yarchoan - Concepedia

Author

Mark Yarchoan

Sidney Kimmel Comprehensive Cancer Center ORCID

Also Known As

Angela Sutton, M Yarchoan, M. Yarchoan, M., Yarchoan, Mark M. Yarchoan, Mark Yarchoan, Yarchoan, Mark

474

Publications

16.8K

Citations

H-Index

109

Concepts

All Affiliations

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Johns Hopkins Medicine Bloomberg (United States)University of Pennsylvania

About

Mark Yarchoan is an author at Sidney Kimmel Comprehensive Cancer Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	32	3.5K
2	Health Sciences	6	6	1.7K
3	Engineering	4	4	135
4	Biochemistry	1	1	200
5	Biomedical Engineering	1	1	62

Mark Yarchoan

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma Amit G. Singal, Josep M. Llovet, Mark Yarchoan, Hepatology Cancer ManagementPathologyAasld Practice GuidanceAlice C.Comparative Literature	2023	1.4K
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers Mark Yarchoan, Lee A. Albacker, Alexander C. Hopkins, JCI Insight	2019	526
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity Won Jin Ho, Qingfeng Zhu, Jennifer N. Durham, Nature Cancer Nivolumab ConvertHepatologyMedicineImmunologyTumor Immunity	2021	327
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias Mark Yarchoan, Sharon X. Xie, Mitchel A. Kling, Brain AgingAlzheimer's DiseaseVascular Risk FactorsNeurologyLewy Body Dementia	2012	260
Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival Ludmila Danilova, Won Jin Ho, Qingfeng Zhu, Cancer Immunology Research	2019	258
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors Adam Diehl, Mark Yarchoan, Alex Hopkins, Oncotarget Solid TumorsImmunologyPharmacotherapyLymphocyte CountsCancer Patients	2017	228
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma Alexander C. Hopkins, Mark Yarchoan, Jennifer N. Durham, JCI Insight	2018	225
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Journal of Clinical Oncology	2024	209
Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies Mark Yarchoan, Jon B. Toledo, Edward B. Lee, Acta Neuropathologica Abnormal Serine PhosphorylationNeurodegenerative DiseasesAlzheimer's DiseaseSignal TransductionBiochemistry	2014	200

Page 1